Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CTMX)

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

GlobeNewswire 2 days ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 2 days ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

GlobeNewswire 3 days ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

GlobeNewswire 9 days ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

GlobeNewswire April 8, 2024

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

GlobeNewswire April 3, 2024

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

GlobeNewswire March 21, 2024

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

GlobeNewswire March 18, 2024

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

GlobeNewswire March 11, 2024
View More News ››

Opinion & Analysis (NDAQ:CTMX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CTMX)

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Stud

Just In: $CTMX Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer...
whytestocks - 1 day ago

The report

So. Nothing tilt he end of the year, then nothign til t eend of next year.  Hmmph.
zalmonella - 1 day ago

CTMX Price Target Alert: $8.00. Issued by Jefferies

Just In: $CTMX CTMX Price Target Alert: $8.00. Issued by Jefferies2024-05-06 00:00:04 ET Roger Song from Jefferies issued a price target...
whytestocks - 4 days ago

CTMX..... Early a.m runner

On watch  Going Skiing...no position  Cheers !
Iseneschal - January 6, 2023

From boom to boot

Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it...
zalmonella - February 2, 2022

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$CTMX $NKTR $MGNX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Silver North Resources Ltd.

Silver North Resources Ltd.

Silver North Resources Ltd., formerly Alianza Minerals Ltd., is a Canada-based company, which is focused on silver ...
View More »